Cardiac Positron Emission Tomography: Current Clinical Practice

Cardiology Clinics

Volumn 27, Issue 2, 2009, Pages 237-255

  Lalonde, Lucille ^a   Ziadi, Maria Cecilia ^b   Beanlands, Rob ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Imaging; Medicine; Molecular; Myocardial perfusion; Myocardial viability; PET; Sarcoidosis; Vasculitis

Indexed keywords

ACETIC ACID C 11; AMMONIA N 13; COPPER 62; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GALLIUM 68; GEPEFRINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PALMITIC ACID C 11; RUBIDIUM 82; STRONTIUM 82; TECHNETIUM 99M; TETROFOSMIN TC 99M; THALLIUM 201; WATER O 15;

CARDIOLOGY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DRUG HALF LIFE; DRUG UPTAKE; ENDOCARDITIS; HEALTH CARE COST; HEART; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART VENTRICLE FUNCTION; HUMAN; IMAGING SYSTEM; MEDICINE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIAL HIBERNATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SCINTIGRAPHY; SYSTOLIC DYSFUNCTION;

DIAGNOSIS, DIFFERENTIAL; HEART DISEASES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 62749198162     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.12.003     Document Type: Review

References (87)

1. Beanlands R., Chow B.J., Dick A., et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced non-invasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multi-detector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease abbreviated report. Can J Cardiol 23 (2007) 107-119
2. Ziadi MC, Beanlands RSB, deKemp RA, et al. Diagnosis and prognosis in cardiac disease using cardiac PET perfusion imaging. In: Zaret BL, Beller GA (editors). Clinical nuclear cardiology: state of the art and future directions. Fourth edition, in press.
3. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med 35 (2005) 17-36
4. Machac J., Bacharach S., Bateman T., et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol 13 (2006) 121-151
5. Schinkel A.F.L., Ferrari R., Bax J.J., et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 32 (2007) 375-410
6. Mullani N.A., Goldstein R.A., Gould K.L., et al. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J Nucl Med 24 (1983) 898-906
7. Wilson R.A., Shea M., Landsheere C.D., et al. Rubidium-82 myocardial uptake and extraction after transient ischemia: PET characteristics. J Comput Assist Tomogr 11 (1987) 60-66
8. Chow B.J., Ananthasubramaniam K., deKemp R.A., et al. Comparison of treadmill exercise versus dipyridamole stress with myocardial perfusion imaging using rubidium-82 positron emission tomography. J Am Coll Cardiol 45 (2005) 1227-1234
9. Bateman T., Heller G., McGhie A., et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 13 (2006) 24-33
10. deKemp R., Yoshinaga K., and Beanlands R. Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?. J Nucl Cardiol 14 (2007) 380-397
11. Beanlands R.S., Hutchins G.D., Muzik O., et al. Heterogenicity of regional nitrogen 13-labeled ammonia tracer distribution in the normal human heart: comparison with rubidium 82 and copper 62-labeled PTSM. J Nucl Cardiol 1 (1994) 225-235
12. Hickey R., Sciacca R., Bokhari S., et al. Assessment of cardiac wall motion and ejection fraction with gated PET using N-13 ammonia. Clin Nucl Med 29 (2004) 243-248
13. Yoshinaga K., Katoh C., Noriyasu K., et al. Reduction of coronary flow reserve in areas with and without ischemia on stress perfusion imaging in patients with coronary artery disease: a study using oxygen 15-labeled water PET. J Nucl Cardiol 10 (2003) 275-283
14. Sun K.T., Yeatman L.A., Buxton D.B., et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using 11-carbon acetate. J Nucl Med 39 (1998) 272-280
15. Green M.A., Mathias C.J., Welch M.J., et al. Copper-62-labeled pyruvaldehyde bis (N4-methylthiosemicarbazonato) copper (II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med 31 (1990) 1989-1996
16. 62Cu-PTSM and 62Cu-ETS. Clinical Nuclear Medicine 25 (2000) 396-402
17. 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med 48 (2007) 1021-1030
18. Yalamanchili P., Wexler E., Hayes M., et al. Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol 14 (2007) 782-788
19. Chow B.J., Beanlands R.S., Lee A., et al. Treadmill exercise produces larger perfusion defects than dipyridamole stress N-13 ammonia positron emission tomography. J Am Coll Cardiol 47 (2006) 411-416
20. Plössla K., Chandraa R., Qua W., et al. A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent. Nucl Med Biol 35 (2008) 83-90
21. Sánchez-Crespo A., Andreo P., and Larsson S. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 31 1 (2004) 44-51
22. Ratib O., Phelps M., Huang S., et al. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med 23 (1982) 577-586
23. 18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation 91 (1995) 2435-2444
24. Sabahat Bokhari S., Ficaro E., McCallister B., et al. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol 14 (2007) 415-416
25. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 5 (1985) 584-590
26. Kauffmann P., and Camici P. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 46 (2005) 75-88
27. Parkash R., deKemp R., Ruddy T., et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel disease. J Nucl Cardiol 11 4 (2004) 440-449
28. Schwaiger M., Ziegler S., Nekolla S., et al. PET/CT: challenge for nuclear cardiology. J Nucl Med 46 (2005) 1664-1678
29. Dorbala S., Kwong R., Di Carli M.F., et al. Value of left ventricular ejection fraction reserve in assessment of severe left main/three-vessel coronary artery disease: a rubidium-82 PET-CT study. J Nucl Med 48 (2007) 349-358
30. Brown T.L., Merrill J., Bengel F.M., et al. Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82-rubidium myocardial perfusion PET. Eur J Nucl Med Mol Imaging 35 (2008) 336-342
31. Lertsburapa K., Ahlberg A., Bateman T., et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 15 (2008) 745-753
32. Klocke F., Baird M., Bateman T., et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging. J Am Coll Cardiol 42 7 (2003) 1318-1333
33. Yoshinaga K., Chow B.J., Beanlands R., et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography?. J Am Coll Cardiol 48 (2006) 1029-1039
34. Schelbert H.R., Phelps M.E., Wisenberg G., et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol 49 (1982) 1197-1207
35. Tamaki N., Senda M., Yonekura Y., et al. Myocardial positron computed tomography with 13N-ammonia at rest and during exercise. Eur J Nucl Med 11 (1985) 246-251
36. Yonekura Y., Senda M., Tamaki N., et al. Detection of coronary artery disease with 13N ammonia and high resolution positron-emission computed tomography. Am Heart J 113 (1987) 645-654
37. Tamaki N., Koide H., Saji H., et al. Value and limitation of stress thallium-201 single photon emission computed tomography: comparison with nitrogen-13 ammonia positron tomography. J Nucl Med 29 (1988) 1181-1188
38. Gould K.L., Goldstein R.A., Mullani N.A., et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82. J Am Coll Cardiol 7 (1986) 775-789
39. Demer L.L., Gould K.L., Goldstein R.A., et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 79 (1989) 825-835
40. Go R.T., Marwick T.H., MacIntyre W.J., et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 31 (1990) 1899-1905
41. Stewart R.E., Molina E., Popma J., et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol 67 (1991) 1303-1310
42. Marwick T.H., Nemec J.J., Salcedo E.E., et al. Diagnosis of coronary artery disease using exercise echocardiography and positron emission tomography: comparison and analysis of discrepant results. J Am Soc Echocardiogr 5 (1992) 231-238
43. Grover-McKay M., Ratib O., Schwaiger M., et al. Detection of coronary artery disease with positron emission tomography and rubidium 82. Am Heart J 123 (1992) 646-652
44. Laubenbacher C., Rothley J., Sitomer J., et al. An automated analysis program for the evaluation of cardiac PET studies: initial results in the detection and localization of coronary artery disease using nitrogen-13-ammonia. J Nucl Med 34 (1993) 968-978
45. Wallhaus T.R., Lacy J., Stewart R., et al. Copper-62-pyruvaldehyde bis (N-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans. J Nucl Cardiol 8 (2001) 67-74
46. Walsh M.N., Bergmann S.R., Kenzora J.L., et al. Delineation of impaired regional myocardial perfusion by positron emission tomography with H2(15)O. Circulation 78 (1988) 612-620
47. Williams B.R., Jansen D.E., Mullani N.A., et al. A retrospective study of the diagnostic accuracy of a community hospital-based PET center for the detection of coronary artery disease using rubidium-82. J Nucl Med 35 (1994) 1586-1592
48. Simone G.L., Mullani N.A., Page D.A., et al. Utilization statistics and diagnostic accuracy of a nonhospital-based positron emission tomography center for the detection of coronary artery disease using rubidium-82. Am J Physiol Imaging 7 (1992) 203-209
49. Sampson U.K., Di Carli M.F., Dorbala S., et al. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol 49 (2007) 1052-1058
50. Husmann L., Kaufmann P.A., Valenta L., et al. Diagnostic accuracy of myocardial perfusion imaging with single photon emission computed tomography and positron emission tomography: a comparison with coronary angiography. Int J Cardiovasc Imaging 24 5 (2008) 511-518
51. Namdar M., Hany T.F., Koepfli P., et al. Integrated PET/CT for the assessment of coronary artery disease: a feasibility study. J Nucl Med 46 (2005) 930-935
52. Study of myocardial perfusion and coronary anatomy imaging roles in CAD (SPARC). Web page Available at:. http://www.sparctrial.org Accessed: September, 2008
53. Neglia D., Michelassi C., Pratali L., et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105 (2002) 186-193
54. Cecchi F., Olivotto I., Gistri R., et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
55. Hachamovitch R., Rozanski A., Hayes S.W., et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?. J Nucl Cardiol 13 (2006) 768-778
56. Marwick T., Shan K., Sanjiv Patel S., et al. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol 80 (1997) 865-870
57. Chow B.J., Yoshinaga K., Williams K., et al. Prognostic significance of dypiridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. J Nucl Med 46 (2005) 1095-1101
58. Shi H., Santana C.A., Rivero A., et al. Normal values and prospective validation of transient ischaemic dilation index in 82Rb PET myocardial perfusion imaging. Nucl Med Commun 28 (2007) 859-863
59. Merhige M., Breen W., Shelton V., et al. Impact of myocardial perfusion imaging with PET and 82Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management. J Nucl Med 48 (2007) 1069-1076
60. Rosamond W., Flegal K., Friday G., et al. Heart Disease and Stroke Statistics -2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
61. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97 (1998) 282-289
62. Braunwald E., and Kloner R.A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66 (1982) 1146-1149
63. Rahimtoola S.H. From coronary artery disease to heart failure: role of the hibernating myocardium. Am J Cardiol 75 (1995) 16-22
64. Di Carli M.F., Asgazadie F., Schelbert H.R., et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 92 (1995) 3436-3444
65. Beanlands R., Ruddy T., deKemp R., et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 40 (2002) 1735-1743
66. Thompson K., Saab G., Birnie D., et al. Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardiomyopathy?. J Nucl Med 47 (2006) 1763-1768
67. Di Carli M.F., Prcevski P., Singh T.P., et al. Myocardial blood flow, function, and metabolism in repetitive stunning. J Nucl Med 41 (2000) 1227-1234
68. Beanlands R.S.B., Ruddy T., et al. 18-Fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease a randomized controlled trial (PARR-2). J Am Coll Cardiol 50 (2007) 2002-2012
69. D'Egidio G., Nichol G., Williams K., et al. Hibernating myocardium identifies high risk patients with ischemic cardiomyopathy. Substudy of the PARR-2 trial. Can J of Card 23 Supp c (2007) 228C
70. Joyce D., Loebe M., Noon G.P., et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol 18 (2003) 454-457
71. Cleland J.G., Freemantle N., Ball S.G., et al. The heart failure revascularization trial (HEART): rationale, design and methodology. Eur J Heart Fail 5 (2003) 295-303
72. Okumura W., Iwasaki T., and Toyama T. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 12 (2004) 1989-1998
73. Ohira H., Tsujino I., and Ishimaru S. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35 (2008) 933-941
74. Ishimaru H., Tsujino I., Takei T., et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26 15 (2005) 1538-1543
75. 18F-FDG PET. J Nucl Med 44 (2003) 1030-1036
76. Kaira K., Ishizuka T., Yanagitani N., et al. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med 32 (2007) 114-116
77. Tawakol A., Migrino R., Hoffmann U., et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 12 3 (2005) 294-301
78. Rudd J., Myers K., Bansilal S., et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 49 6 (2008) 871-878
79. Meller J., Grabbe E., Becker W., et al. Value of F-18 FDG hybrid camera PET and MRI in early takayasu aortitis. Eur Radiol 13 (2003) 400-405
80. Hauser M., Bengel F., Kuehn A., et al. Myocardial blood flow and coronary flow reserve in children with "normal" epicardial coronary arteries after the onset of Kawasaki disease assessed by positron emission tomography. Pediatr Cardiol 25 2 (2004) 108-112
81. Furuyama H., Odagawa Y., Katoh C., et al. Assessment of coronary function in children with a history of Kawasaki disease using (15) O-water positron emission tomography. Circulation 105 24 (2002) 2878-2884
82. Yen R.F., Chen Y.C., Wu Y.W., et al. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis: a preliminary report. Acad Radiol 11 3 (2004) 316-321
83. Mielniczuk L., DeKemp R.A., Dennie C., et al. Images in cardiovascular medicine. Fluorine-18-labeled deoxyglucose positron emission tomography in the diagnosis and management of aortitis with pulmonary artery involvement. Circulation 111 (2005) e375-e376
84. Valette H., Syrota A., and Merlet P. Use of PET radiopharmaceuticals to probe cardiac receptors. In: Schwaiger M. (Ed). Cardiac positron emission tomography (1996), Kluwer Academic Publishers, Boston 331-351
85. Fallavollita J.A., Luisi Jr. A.J., Michalek S.M., et al. Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. Contemp Clin Trials 27 (2006) 374-388
86. 11C acetate PET. Can J Cardiol 11 (1995) 293-300
87. Gropler R.J. Pet measurements of myocardial metabolism. In: Di Carli M.F., and Lipton M.J. (Eds). Cardiac PET and PET/CT imaging (2007), Springer 227-249